Loading...

IMNM IMMUNOME INC US FDA Inspections 8-K Filing

MMNM

MNM

IMMUNOME INC

(IMNM)

2025 8-K

Financial Results Update

Financial Results Update

Stock Offering Announcement

Positive Clinical Results

Financial Results Update

Financial Statements

Increase in common stock re...

Financial Results

Public Offering

CFO Relocation Package

Q3 Financial Results

Asset Acquisition

Equity Award Plan

Q2 Financial Results

Financial Results and Busin...

Resignation and Appointment

Appointment of Sandra Swain...

Financial Results Announcement

Asset Acquisition

Public Offering

Asset Purchase Agreement

Promotion and Compensatory ...

Presentation Update

License Agreement and Stock...

Appointment of Director and...

Departure of Directors or C...

Acquisition Agreement

Amendment to Merger Filing

Presentation Update

Financial Results Announcement

Appointment of Director

Merger and Amendments

Financial Results Announcement

Investor Meetings

Merger Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Collaboration Agreement wit...

Agreement with Whitehead In...

External Links:

Immunome Inc. reported positive topline results from its Phase 3 RINGSIDE trial of varegacestat on December 15, 2025, showing an 84% reduction in disease progression risk and a 56% objective response rate compared to placebo. This is a significant event as the company plans to submit a New Drug Application to the FDA in Q2 2026.

AI Assistant

IMMUNOME INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.